Analyzing Jazz Pharmaceuticals Stock – Key Insights

By Harris Dyer • Tuesday, February 11 15:07 • Permanent Link

Mid-cap Health Care company Jazz Pharmaceuticals has moved 5.3% so far today on a volume of 835,300, compared to its average of 579,238. In contrast, the S&P 500 index moved 0.0%.

Jazz Pharmaceuticals trades -28.31% away from its average analyst target price of $181.37 per share. The 19 analysts following the stock have set target prices ranging from $128.0 to $230.0, and on average have given Jazz Pharmaceuticals a rating of buy.

Anyone interested in buying JAZZ should be aware of the facts below:

Jazz Pharmaceuticals's current price is 54.1% above its Graham number of $84.36, which implies that at its current valuation it does not offer a margin of safety
Jazz Pharmaceuticals has moved 1.4% over the last year, and the S&P 500 logged a change of 22.5%
Based on its trailing earnings per share of 7.06, Jazz Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 18.4 while the S&P 500 average is 29.3
JAZZ has a forward P/E ratio of 6.0 based on its forward 12 month price to earnings (EPS) of $21.56 per share
Its Price to Book (P/B) ratio is 1.88 compared to its sector average of 3.53
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
Based in Dublin, the company has 2,800 full time employees and a market cap of $7.86 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.